Compare CRSP & CVLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSP | CVLT |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 6.1B |
| IPO Year | 2016 | 2006 |
| Metric | CRSP | CVLT |
|---|---|---|
| Price | $56.70 | $127.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 13 |
| Target Price | $71.50 | ★ $193.83 |
| AVG Volume (30 Days) | ★ 1.8M | 761.3K |
| Earning Date | 02-10-2026 | 01-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.76 |
| Revenue | $38,337,000.00 | ★ $1,095,835,000.00 |
| Revenue This Year | N/A | $19.22 |
| Revenue Next Year | $723.84 | $12.47 |
| P/E Ratio | ★ N/A | $72.83 |
| Revenue Growth | N/A | ★ 22.02 |
| 52 Week Low | $30.04 | $114.47 |
| 52 Week High | $78.48 | $200.69 |
| Indicator | CRSP | CVLT |
|---|---|---|
| Relative Strength Index (RSI) | 51.43 | 51.30 |
| Support Level | $54.50 | $118.00 |
| Resistance Level | $59.18 | $128.77 |
| Average True Range (ATR) | 2.87 | 3.79 |
| MACD | 0.33 | 1.84 |
| Stochastic Oscillator | 44.03 | 91.05 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
CommVault Systems Inc provides data and information management software applications and services. The firm sells software licenses and services to large global enterprises, small- and midsize businesses, and government agencies through both its salesforce and its network of reseller partners. Its software solutions include Cleanroom Recovery, HyperScale X, Air Gap Protect, Compliance, Cloud Rewind, and Clumio Backtrack. The company operates in the United States and exports to many other countries.